comparemela.com

Latest Breaking News On - Evelyn byrd - Page 1 : comparemela.com

Transcripts For BLOOMBERG On The Move With Rishaad Salamat 20141208

Over to tokyo. Sherry and is live. How bad the numbers were . Rish, it was quite surprising to see that revised gdp data out of japan today. The gdp shrinking an annualized 1. 9 and the third quarter. More than the initial breeding off contraction of 1. 6 first it. It was quite unexpected. Gave a the 24 economists figure that low. We had expected gdp data to be revised upwards. This figure showing the japanese economy is in a much deeper recession than originally thought. That will be a below to Prime Minister shinzo abe in the election season where we have less than a week to go to vote on sunday. Chari, lets discuss as he goes to the polls, he has a whole host of issues. Can you walk us through some of the key ones . Rish, a lot of Unfinished Business for the japanese Prime Minister. Three key issues. Lets get started with inflation, prices. Inflationary policies and not quite there. Rising only 0. 9 in october. When you strip the april sales tax hike. To carryay be forced out even m

Transcripts For CSPAN2 Book TV 20130720

Submitted to the fda came from hundreds of patients. If you had used ten patients, its like studying twins in a way because its all the same disease. So if they had used ten patients and given a kind of conditional approval, then everyone would have gotten the drug a lot faster possibly. So things like that, you know, could be in the are in the works. But its difficult to get them working. Jessica, youve outlined the fda is coming up with a new designation, a breakthrough designation status which really fast tracks drugs perfectly. It puts the companies in contact with the data and helps them shepherd it through very quickly. But these Breakthrough Status are for these targeted drugs meaning with cml the package actually is about a thousand patients. But the response we got in the first hundred was the same we got in the last hundred. And so the reality is if we could have taken that first hundred and had a breakthrough designation status, we could have had this on the market in a year

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.